1. Home
  2. NRC vs TRDA Comparison

NRC vs TRDA Comparison

Compare NRC & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Research Corporation (Delaware)

NRC

National Research Corporation (Delaware)

HOLD

Current Price

$14.04

Market Cap

428.2M

Sector

Health Care

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$11.65

Market Cap

438.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRC
TRDA
Founded
1981
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
428.2M
438.8M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
NRC
TRDA
Price
$14.04
$11.65
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$20.00
AVG Volume (30 Days)
124.6K
179.9K
Earning Date
05-05-2026
05-25-2026
Dividend Yield
4.88%
N/A
EPS Growth
N/A
N/A
EPS
0.43
N/A
Revenue
$119,686,000.00
$25,421,000.00
Revenue This Year
N/A
$51.37
Revenue Next Year
N/A
$46.98
P/E Ratio
$30.72
N/A
Revenue Growth
1.81
N/A
52 Week Low
$9.76
$4.93
52 Week High
$22.79
$12.93

Technical Indicators

Market Signals
Indicator
NRC
TRDA
Relative Strength Index (RSI) 45.57 52.23
Support Level $12.74 $9.59
Resistance Level $14.20 $12.18
Average True Range (ATR) 0.86 0.77
MACD 0.29 0.04
Stochastic Oscillator 86.21 46.01

Price Performance

Historical Comparison
NRC
TRDA

About NRC National Research Corporation (Delaware)

National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: